换一批
换一批Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
作者：
主题词
抗肿瘤药(Antineoplastic Agents);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);脱氧胞苷(Deoxycytidine);多柔比星(Doxorubicin);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);药物协同作用(Drug Synergism);女(雌)性(Female);人类(Humans);桩蛋白(Paxillin);嘧啶类(Pyrimidines);信号传导(Signal Transduction);紫杉烷类(Taxoids);噻唑类(Thiazoles);托泊替坎(Topotecan);src族激酶类(src-Family Kinases)
DOI
10.1097/IGC.0000000000000056
PMID
24407585
发布时间
2022-12-07
- 浏览22
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
